[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Liu Hongfang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":59},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100595619","yiqijiangzhuohuoxuetongluo-method-to-delay-the-occurrence-of-end-stage-renal-disease-in-diabetic-kidney-disease--study2-100595619",false,"NCT07034807","YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study2","Evidence-based Evaluation of Yiqi Jiangzhuo Huoxue Tongluo Method in Delaying the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study 2","Inclusion Criteria:\n\n* 1 In line with the diagnostic criteria of Western medicine type 2 DKD ;\n* 2 18-80 years old, regardless of gender ;\n* 3 30ml \u002F min \u002F 1.73m2 ≤ eGFR \\\u003C 60ml \u002F min \u002F 1.73m2 ( eGFR was calculated according to CKD-EPI formula ) ;\n* 4 In line with the diagnostic criteria of qi deficiency and collateral stasis syndrome in traditional Chinese medicine ;\n* 5 hbA1c between 7-10 % ;\n* 6 uACR ≥ 300mg \u002F g\n* 7 blood pressure ≤ 150 \u002F 90mmHg ;\n* 8 signed the informed consent ;\n\nExclusion Criteria:\n\n* 1 Patients who are currently receiving other traditional Chinese medicines and Chinese patent medicines with DKD therapeutic effects ;\n* 2 combined with other clear renal diseases, such as polycystic kidney disease, glomerulonephritis, renal tumors ;\n* 3 Patients with acute or chronic infection who needed treatment were judged by the researchers not suitable for inclusion in the study ;\n* 4 Patients who participated in any other research drug study and \u002F or received or had received another research drug or intervention treatment ( within one month before signing the informed consent form ) ;\n* 5 patients who were allergic or contraindicated to the planned use of drugs ;\n* 6 There are serious acute or chronic diseases that the major researchers believe may pose an excessive risk to the subjects, including : patients with cardiovascular, cerebrovascular, lung, blood, digestive tract, liver, kidney, neuropsychiatric or infectious diseases ;\n* 7 Patients with a history of immunodeficiency, including patients with other acquired, congenital immunodeficiency diseases, or patients with a history of organ transplantation or planned organ transplantation ;\n* 8 Women with positive pregnancy screening test or lactating or planning to get pregnant in the next 24 months. Female or male patients who were reluctant to use contraception throughout the study period ;\n* 9 patients with a history of malignant tumors within 5 years ;\n* 10 patients with type 1 diabetes ;\n* 11 patients with maintenance dialysis \\> 2 weeks and \u002F or expected maintenance dialysis \\> 8 weeks before treatment and patients who were judged by any researcher not suitable for inclusion in the trial.","ALL","18 Years","80 Years",{"count":20,"type":21},228,"ESTIMATED","INTERVENTIONAL",[24],"NA","Using the practical randomized controlled trial designed by Zelen, the subjects were randomly divided into the experimental group and the control group. The experimental group was given the traditional Chinese medicine prescription ' Shenzhuo Decoction ' ( composed of Astragalus membranaceus, Salvia miltiorrhiza, Leech, Raw Rhubarb, Epimedium, Motherwort ) + basic treatment ( including nutrition, lifestyle, hypoglycemic, hypotensive, lipid-lowering, control of other risk factors, etc. ), the control group was given basic treatment, a total of 1 year of drug intervention, followed up for 1 year.",[27],"Diabetic Kidney Disease (DKD)","NOT_YET_RECRUITING","2025-06-20",{"date":31,"type":32},"2025-06-24","ACTUAL",{"date":34,"type":21},"2025-08-01",{"date":36,"type":21},"2028-07-31",{"name":38,"class":39},"Liu Hongfang","OTHER",5,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":57,"leadSponsor":58,"locationsCount":40},"100595412","yiqijiangzhuohuoxuetongluo-method-to-delay-the-occurrence-of-end-stage-renal-disease-in-diabetic-kidney-disease--study1-100595412","NCT07032116","YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study1","Evidence-based Evaluation of Yiqi Jiangzhuo Huoxue Tongluo Method in Delaying the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study 1","Inclusion Criteria:\n\n* 1 in line with Western medicine diagnostic criteria for type 2 diabetic kidney disease ;\n* 2 18-80 years old, regardless of gender ;\n* 3 eGFR \\> 15ml \u002F ( min · 1.73m2 ) ; the eGFR was calculated according to the chronic kidney disease epidemiology collaboration equation ( CKD-EPI ).\n* 4 In line with the diagnostic criteria of qi deficiency and collateral stasis syndrome in traditional Chinese medicine ;\n* 5glycosylated hemoglobin ( HbA1c ) between 7-10 % ;\n* 6 blood pressure ≤ 160 \u002F 100mmHg ;\n* 7 to sign the informed consent ;\n\nExclusion Criteria:\n\n* 1 combined with other clear renal diseases, such as polycystic kidney disease, glomerulonephritis, renal tumor, etc. ;\n* 2 patients with a history of recurrent genitourinary tract infection ;\n* 3 combined with cardiovascular and cerebrovascular, digestive, respiratory, urinary, immune system serious diseases or mental diseases ;\n* 4 currently in pregnancy, lactation, or pregnancy plan women ;\n* 5 Patients with type 1 diabetes.\n* 6 Tumor patients undergoing radiotherapy, chemotherapy or targeted therapy.",{"count":49,"type":21},4472,"OBSERVATIONAL","In order to reduce the clinical demand for kidney dialysis rate of Diabetic Kidney Disease（DKD） patients, a bidirectional cohort study of 4472 patients with DKD (Qi deficiency and collateral stasis syndrome) was carried out based on a preliminary DKD cohort of 13,000 patients. The exposure factor was supplementing and reducing the kidney turbidity-Huoxue Tongluo method represented by the addition and subversion of Shenzhuo prescription, and the incidence of end-stage renal disease was the main therapeutic index. Follow-up was conducted for 2 years",[27],"2025-06-13",{"date":55,"type":32},"2025-06-22",{"date":34,"type":21},{"date":36,"type":21},{"name":38,"class":39},""]